903

López-Fando Lavalle L¹, Sánchez Gallego M D¹, Jiménez Cidre M Á¹, Gómez de Vicente J M¹, Burgos Revilla F J¹

1. Hospital Ramón y Cajal

THREE DAYS BLADDER DIARY IN WOMEN: TEN YEARS SUPPORTS UTILITY

Hypothesis / aims of study

LUTS are still a diagnosis challenge as Health Technology Assessment systematic review demonstrates in 2006. On it, bladder diary appears to be the most cost-effective of the three primary care tests (diary, pad test and validated scales) used in addition to clinical history. Since that date there were an increased interest in the need of making new studies in order to standardize diagnosis tests.

In 2006, guidelines still suggest the use of bladder diary (BD) in the initial evaluation of patients with LUTS with an A grade of recommendation. Although, there is no agreement in the best duration of BD, guidelines recommend a 3-7 days length (B grade). Our Functional Urology and Urodynamics Group, has developed since 2006 a 3 days bladder diary (3dBD) wich has proved being useful in overactive bladder (OAB) diagnosis in women in our Center and in subsequent postvalidation studies (1).

The objective of this abstract is to summarize ten years of developing works of our group about 3dBD in women and their conclusions.

Study design, materials and methods

We made a review of published articles by our Functional Urology and Urodynamics Group from 2006 to 2016 related to 3dBD in women

Interpretation of results

Results Charter 1. Describes basics studies characteristics

| STUDY | N | Study design | Variables | Comparison test | Convergent validity | Statistical test for efficacy |
|-----------------------|-----|---|-----------------------------|---------------------------|--|---|
| Design and validation | 136 | Descriptive Cross-sectional Prospective | 3dBD Test and retest | BSAQ UDS ICIQ-UI SF | Kappa ICC Spearman correlation coefficient | Feasibility Reliability Interobserver reliability Convergent validity |
| Unicentre | 199 | Transversal Cross-sectional | 3dBD | CR UDS | Kappa ICC | Cost-efficacy |
| Multicentre | 247 | Observational Cross-sectional | 3dBD | BSAQ PPIUS UDS | Kappa ICC | Diagnosis efficiency |
| Contradictions | 56 | Retrospective | Mistakes and contradictions | BD3d | Correlation | |

BSAQ: bladder control self-assessment questionnaire.

UDS: Urodynamics investigation

ICIQ: International Consultation on Incontinence modular Questionaire

PPIUS: Patient Perception of Intensity of Urinary Scale

ICC: intraclass correlation coefficient

CR: clinical record

Charter 2. Studies results and conclusions

| STUDY | Filling out | Test Re-Test | Convergent validity USD | Convergent validity Questionaires | Efficacy |
|-----------------------|--|---|-------------------------|--|--|
| Design and validation | Test: - 77.2% Re-test (15 days): 77.9% | Qualitative (urgency, incontinence, nocturia, frequency): no statistically significant differences Quantitative: ICC 0.7-0.9 | No agreement | ICIQ-UI SF: moderate BSAQ moderate | - Feasibility: high - Reliability: Urgency, UUI, frequency, nocturia: good - Interobserver reliability: good - Convergent validity: moderate |
| Unicentre | 100% fully completed | | No agreement | CR: moderate agreement | Best cost-efficacy: CR + 3dBD. Sensibility: 94%. Non invasive. |
| Multicentre | 85.4-96.8% tests completed | | No agreement | PPIUS: poor BSAQ: poor | Best OAB diagnosis efficiency: 3dBD + BSAQ |
| Contradictions | 100% fully completed | | | PPIUS: 51.3% Contradictions Kind of urinary incontinence: 46.3% Contradictions | |

Concluding message

3dBD is a very useful tool in LUTS evaluation. Based in our experience and published literature, we can conclude It constitutes a great source of information in daily practice, and combined with clinical record and validated questionnaires like BSAQ, are the most cost effective diagnosis test in OAB.

References

1. "The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women" Jiménez Cidre et al. Neurourol Urodyn. 2015 Feb;34(2):128-32. 2013 Nov 22.

Disclosures

Funding: Astellas speaker Clinical Trial: No Subjects: NONE